![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 19, 2025
This companion study aims to build a biobank of tumor tissue samples to identify factors driving breast cancer recurrence despite treatment
December 19, 2025
Timely updates on research leaders, presentations at medical meetings and more
November 21, 2025
A recap of the Fall 2025 Group Meeting, trial results from ESMO, and a look ahead to the ASH Annual Meeting and Exposition and the San Antonio Breast Cancer Symposium
November 21, 2025
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2025 Group Meeting
November 21, 2025
In an annual evaluation, 37 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 21, 2025
Compliance guidance for an updated policy that aims to accelerate free public access to research funded by the National Institutes of Health
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
October 17, 2025
A welcome to the new National Cancer Institute director, an update on the federal budget and its implications, and a look ahead to next week's Group Meeting
October 23, 2025
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer
October 17, 2025
Dr. Reid’s research focuses on young-onset breast cancer, hereditary breast cancer, and population-based differences in breast cancer outcomes
September 5, 2025
This clinical trial is testing a new treatment approach for patients with gastric carcinomatosis
September 19, 2025
Changes broaden eligibility for this study of how adverse life experiences alter genes, immune cells, and subsequent health outcomes